Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Bert Vrijhoef - PANAXEA - RotterdamTechCity - 12 JULY2017


Published on

GlobalTech.City is founded in 2017 and is the global platform connecting AmsterdamTech.City and the other tech cities around the world.

The vision of AmsterdamTech.City is to combine city events, tech topics, societal challenges, tech solutions, and speakers for the city, communities, and citizens of Amsterdam. The mission of AmsterdamTech.City is to facilitate the city, communities, and citizens in the engagement and transformation.

The target groups are public and private; governmental and non-governmental; educational institutions, teachers and students; corporates, scale ups and start ups; investors and programs, inventors and experts; visitors and citizens. The speakers are presenting challenges and solutions. They are government officials, civil servants, citizens, visitors, students, teachers, experts, inventors, investors, start ups, scale ups, corporates.

The latest technology trends are the topics of the events and solutions. In 2016 the tech trends were Internet of Things (IoT), Artificial Intelligence (AI), Blockchain, and Big Data. In 2017 more tech trends will follow. The events are called “Tech & The city” where tech is replaced by the tech topic. The challenges are city or civic problems and issues. Examples are Education, Health, Mobility / Transportation, Connectivity, Sustainability, and many more. The solutions are tech solutions for the city or civic problems and issues. The tech solutions are based on the latest tech trends.

  • Be the first to comment

  • Be the first to like this

Bert Vrijhoef - PANAXEA - RotterdamTechCity - 12 JULY2017

  1. 1. Unlocking the value of (bio)medical and healthcare innovations Dr. Bert Vrijhoef | CIO on behalf of the Panaxea Team The Health Intelligence Company
  2. 2. (Bio)Medical and Healthcare Innovation: 
 a Changing Game
  3. 3. A Changing Game Notwithstanding the increasing need for innovation in health care: • Having something new (combined with provider or patient pull) is just not sufficient anymore • Getting an innovation to the clinic is increasingly dependent on: – How the innovation holds up in the era of (comparative) evidence-based medicine – Setting and managing a sustainable target price, based on the innovations’ added value – Payers have become players
  4. 4. Payers have become players It is not enough to know: – That an innovation ought to work – That it makes sense – That we can do it, or that an expert vouches for it – That it works in mice, rats or petri dishes It is nice to know, but still not sufficient: – That it lowers blood pressure, normalizes heart rhythms, ... – That it has better imaging or diagnostic quality Instead, they need to know: – Does it actually extend lives and/or improve quality of life? – What are the risks, potential harms? – What are the net changes in total costs of care including upfront and downstream cost impacts?
  5. 5. Payers have become players Payers want to be convinced about “value for money” before the innovation enters next development stages or clinical practice Do not adopt Trade- off Trade- off Adopt costs effects + − + −
  6. 6. Payers and other players ▪ Different stakeholders experience different benefits and burdens ▪ Stakeholders have different decision drivers and evidence needs
  7. 7. Panaxea Addresses questions regarding: ▪ Business development and strategy ▪ (Re-)design of new service, product, or pathway ▪ Implementation of new service, product, or pathway ▪ Added value of new services, products, or pathways ▪ Market access & reimbursement ▪ Implementation/ evaluation of new products/ interventions in care pathway “Intuitively, my product means enormous value to the patient. How do I convey the added value potential of my product the stakeholders including investors, payers, patients health care providers?” “Users are complaining about the high cost of the product, but they do not realize the cost savings down the care pathway. How can I clarify this?” “My product is not taken up by healthcare providers. How can I increase market penetration?” “What is the savings potential of my product?” “What is a an acceptable, value-based price range for my new product?”
  8. 8. Strategic Market Access ▪ Panaxea offers strategic advice in early stage of a company’s product development process to accelerate market access. Unlocking the value of your (bio)medical and healthcare innovations ▪ Focuses on: – Accelerating patient access to (bio)medical innovations – Building scientific evidence to inform strategic development, pricing and reimbursement decisions – Evaluate and monitor health care innovations or pathways ▪ With state-of-the-art academic methodology/ tools Panaxea provides excellence in services such as: Health Economic Modeling ▪ Panaxea offers health economic expertise to model clinical, economic and humanistic impact, even at the earliest stages of biomedical product development. New Models of Care Delivery ▪ New care models incl. integration of social and health care, pathways, bundled payments; ▪ Substitution of care between health-care professionals and organizations incl. transitions of care and self-care; ▪ E-health: new business models, implementation fidelity, cost-effectiveness.
  9. 9. Payback from research analysis; Strategic business case; Conceptualization of new models of care delivery; Multi-criteria decision analysis; Health economic evaluations; Health services and policy research; Horizon scanning; Clinical trial simulation; Value of Information analysis; Reimbursement strategy and planning; Value dossiers D – Implementation and monitoring of new models of care delivery; Health services and policy research Panaxea along the Medtech Product Development Process R&D decision Observed need Investment decision Market decision Concept development Product development Post market development A B DC A – Market Analysis; Priority setting B – Headroom analysis C – Product development support; MTA or health economic model;
  10. 10. Projects Selection of projects Developing an innovative in-vitro diagnostic medical device for early diagnosis of Lyme disease Problem definition: • Challenges in the commercialization pathway e.g. gaining market access • Lack of formal value-based reimbursement procedures for diagnostic tests Panaxea’s expertise: • Developing a country-specific reimbursement roadmap and strategy (including options for conditional as well as permanent reimbursement) • Performing a detailed health technology assessment of the innovative test to demonstrate its cost-effectiveness from a payer perspective and the diagnostic lab perspective
  11. 11. Selection of our clients and partners 
 European Commission 
 Roche Thermofisher 
 Belgian Health Care Knowledge Centre 
 Mellon Medical 
 Acutus Medical 
 Nutricia CSL Behring H2020-ESCAPE-NET: European Sudden Cardiac Arrest network: towards Prevention, Education and New Treatment H2020-CRADL: Continuous Regional Analysis Device for neonate Lung MAFEIP: Monitoring and Assessment Framework for the EIP on Active and Healthy Ageing in collaboration with EC JRS 

  12. 12. Team Lotte M.G. Steuten, PhD, MSc Chief Scientific Officer, Co-Founder Isabelle Lepage-Nefkens, PhD, MPH Chief Executive Officer Hubertus J.M. Vrijhoef, PhD, MSc Chief Innovation Officer Daan Mathijssen, MSc Consultant Anam Ahmed, MSc Consultant Liset Grooten, MSc Affiliate Junior researcher Janne Mewes, PhD Senior consultant
  13. 13. Thank you! @PANAXEA The Health Intelligence Company